AT-406 (SM-406): Orally Bioavailable IAP Inhibitor for Apoptosis Pathway Activation

Executive Summary: AT-406 (SM-406) is a small molecule antagonist of multiple inhibitor of apoptosis proteins (IAPs), with nanomolar affinity for XIAP, cIAP1, and cIAP2 (APExBIO product page). It directly induces apoptosis by antagonizing IAP-mediated caspase inhibition and triggers rapid cIAP1 degradation, activating key cell death pathways. AT-406 exhibits potent in vitro activity in human ovarian cancer cell lines (IC50: 0.05–0.5 μg/mL) and enhances sensitivity to carboplatin. In vivo, it demonstrates good oral bioavailability and significant anti-tumor efficacy in mouse xenograft models. Clinical studies indicate tolerability at oral doses up to 900 mg in cancer patients (bioRxiv 2024).

Biological Rationale

Apoptosis is a tightly regulated form of programmed cell death critical for tissue homeostasis and defense against malignancy. Inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2 regulate apoptosis by directly binding and inhibiting executioner caspases (caspase-3, -7) and initiator caspase-9. Overexpression of IAPs in cancer cells leads to impaired apoptotic signaling, supporting tumor survival, chemoresistance, and progression (Background: AT-406 as reference tool). Targeting IAPs restores apoptotic potential, presenting a validated strategy for cancer therapy. AT-406 (SM-406) was developed to antagonize multiple IAPs, thereby reactivating the apoptotic machinery in cancer cells and enhancing the efficacy of chemotherapeutics like carboplatin (Synergy in ovarian cancer cells).

Mechanism of Action of AT-406 (SM-406)

AT-406 (SM-406) is a Smac mimetic that binds to the baculoviral IAP repeat 3 (BIR3) domain of XIAP and the BIR domains of cIAP1 and cIAP2, with reported Ki values of 66.4 nM (XIAP), 1.9 nM (cIAP1), and 5.1 nM (cIAP2) (APExBIO). This competitive inhibition releases caspase-3, -7, and -9 from IAP-mediated suppression, driving the execution phase of apoptosis. Additionally, AT-406 induces rapid proteasomal degradation of cIAP1, resulting in activation of noncanonical NF-κB signaling and autocrine TNFα production, further amplifying apoptotic signaling (Mechanistic insights and translational promise). In cellular systems, these effects are observed within 24 hours at concentrations as low as 0.1 μM.

Evidence & Benchmarks

• AT-406 (SM-406) antagonizes XIAP, cIAP1, and cIAP2 with nanomolar Ki values (66.4 nM, 1.9 nM, and 5.1 nM, respectively) (APExBIO).
• In vitro, AT-406 exhibits IC50 values of 0.05–0.5 μg/mL in human ovarian cancer cell lines, indicating potent cytotoxicity (https://www.apexbt.com/at-406-sm-406.html).
• AT-406 sensitizes ovarian cancer cells to carboplatin, leading to synergistic cell death compared to single-agent treatments (Ovarian cancer synergy).
• In vivo, oral administration of AT-406 in mouse xenograft models of ovarian and breast cancer significantly inhibits tumor progression and prolongs survival (https://www.apexbt.com/at-406-sm-406.html).
• Pharmacokinetic studies in multiple species confirm good oral bioavailability and suitable half-life for daily administration (APExBIO).
• Clinical data show oral doses up to 900 mg are well tolerated in patients with various cancers (bioRxiv 2024).

Applications, Limits & Misconceptions

AT-406 (SM-406) is primarily used in research on apoptosis modulation, cancer biology, and therapeutic development targeting IAP signaling. Its multi-target activity makes it suitable for evaluating apoptotic pathway integrity, screening for IAP-dependent resistance, and validating combination strategies with chemotherapeutics. Application protocols recommend 24-hour exposures at 0.1–3 μM in cell lines to measure cell death and caspase activation (Practical protocol optimization—this article extends the discussion by systematically detailing mechanistic benchmarks and clinical translation).

Common Pitfalls or Misconceptions

• AT-406 is not effective in cell lines lacking functional caspase-3, -7, or -9, as its mechanism requires intact apoptotic machinery.
• Solubility is limited in aqueous buffers; DMSO or ethanol (≥27.65 mg/mL) must be used for stock solutions.
• Chronic storage of solutions at room temperature leads to degradation; short-term use and -20°C storage are recommended.
• Single-agent AT-406 may be insufficient in tumors with alternative cell death resistance mechanisms (e.g., upregulation of Bcl-2 family proteins) (Reference tool: scope and boundaries—this article updates the clinical tolerability context).
• AT-406 is not a pan-cytotoxic agent and does not induce necrosis or autophagy directly.

Workflow Integration & Parameters

• Recommended working concentrations: 0.1–3 μM in cell culture, 24-hour exposure.
• Solvent: Prepare stocks in DMSO or ethanol at concentrations ≥27.65 mg/mL; avoid water due to poor solubility.
• Storage: Solid at -20°C; solutions for short-term experimental use only.
• Readouts: Apoptosis quantification (Annexin V/PI, caspase activity, PARP cleavage), cell viability (MTT, CellTiter-Glo), and synergy with chemotherapeutics.
• For in vivo studies, oral gavage is preferred; refer to pharmacokinetics (species-dependent).

For in-depth troubleshooting and protocol optimization, see the scenario-driven guidance in AT-406 (SM-406): Reliable IAP Inhibition for Reproducible Results—this article clarifies experimental boundaries and cross-validates efficacy benchmarks.

Conclusion & Outlook

AT-406 (SM-406), available from APExBIO, stands as a robust, orally bioavailable IAP inhibitor with well-characterized mechanistic and translational properties. Its nanomolar affinity for key IAPs and capacity to restore apoptosis in chemoresistant cancer models underpin its value for cancer research and therapeutic development. Continued integration with CRISPR-based pathway screens and combination regimens is expected to further expand its impact in apoptosis signaling and translational oncology. For comparative context on apoptosis modulation strategies, see Rewiring Apoptosis Pathways for Translational Success—this article extends mechanistic granularity and updates clinical evidence.